Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
An GZ et al. | 2015 | intact cell/cell culture, BALB/3T3 cells (embryonal mouse fibroblasts) | magnetic field, 50/60 Hz | 2.3 mT |
Liu Y et al. | 2016 | intact cell/cell culture, GC-2 cells (murine spermatocyte-derived cell line) | magnetic field, 50/60 Hz | 1–3 mT |
Cios A et al. | 2021 | intact cell/cell culture, HEK293 (kidney cells), 786-O, 769-P, and Caki1 (clear cell renal carcinoma cell lines) | magnetic field, 50/60 Hz | 4.5 mT |
Tokalov SV et al. | 2003 | intact cell/cell culture, HL-60 cells (human acute myeloid leukaemia cell line) | magnetic field, 50/60 Hz, also other exposures without EMF, co-exposure | 60 µT |
Yadamani S et al. | 2020 | - | magnetic field, 50/60 Hz, also other exposures without EMF, co-exposure | - |
Ramazi S et al. | 2023 | intact cell/cell culture, MCF-7 (human breast cancer cell line) and HFF cells (human foreskin fibroblast cells) | magnetic field, 50/60 Hz, also other exposures without EMF, co-exposure | - |
Schimmelpfeng J | 1997 | intact cell/cell culture, HL-60 (human promyelocytic leukemia cells) | magnetic field, 50/60 Hz, co-exposure | 2 mT |
Dees C et al. | 1996 | intact cell/cell culture, MCF-7 and T-47D cell lines (human breast cancer cell lines) | magnetic field, 50/60 Hz, co-exposure | 1.2–900 µT |
Markkanen A et al. | 2001 | yeast (<i>Saccharomyces cerevisiae</i>/SEy2101a) | magnetic field, 50/60 Hz, co-exposure | 120 µT |
Ding GR et al. | 2001 | intact cell/cell culture, MCF-7 (human breast cancer cell line) | magnetic field, 50/60 Hz, co-exposure | 5 mT |
Tian F et al. | 2002 | intact cell/cell culture, CHO-K1 (Chinese hamster ovary K1) cells (Ku80-proficient) und xrs5 cells (Ku80-defizient; radiation sensitive mutant isolated from CHO-K1 cells) | magnetic field, 50/60 Hz, co-exposure | 5 mT |
Richard D et al. | 2002 | intact cell/cell culture, human diploid amniotic fluid cells | magnetic field, 50/60 Hz, co-exposure | 1 mT |
Tokalov SV et al. | 2003 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells) | magnetic field, 50/60 Hz, co-exposure | 60 µT |
Markkanen A et al. | 2008 | intact cell/cell culture, L929 cells (murine fibroblast cells) | magnetic field, 50/60 Hz, co-exposure | 100–300 µT |
Brisdelli F et al. | 2014 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz, co-exposure | 0.01–2 mT |
Giorgi G et al. | 2014 | intact cell/cell culture, human neuroblastoma cell line (BE(2)C) | magnetic field, 50/60 Hz, co-exposure | 1 mT |
Jin H et al. | 2015 | intact cell/cell culture, L123 cells (human lung epithelial cells) | magnetic field, 50/60 Hz, co-exposure | 1–2 mT |
Martinez MA et al. | 2016 | intact cell/cell culture, NB69 cells (human neuroblastoma cells) | magnetic field, 50/60 Hz, co-exposure | 100 µT |
Luukkonen J et al. | 2017 | intact cell/cell culture, human neuroblastoma cell line (SH-SY5Y) | magnetic field, 50/60 Hz, co-exposure | 100 µT |
Lange S et al. | 2004 | intact cell/cell culture, human amniotic fluid cells (AFC) | magnetic field, 50/60 Hz, co-exposure, also other exposures without EMF | 1 mT |
Livingston GK et al. | 1991 | intact cell/cell culture, human peripheral blood lymphocytes and Chinese hamster ovary (CHO) cells | magnetic field, 50/60 Hz, electric current application | 0.22 mT |
Koziorowska A et al. | 2017 | intact cell/cell culture, pig anterior pituitary gland cells | magnetic field, 50/60 Hz, low frequency | 2–6 mT |
Xu A et al. | 2020 | - | magnetic field, 50/60 Hz, low frequency | - |
Sendera A et al. | 2024 | intact cell/cell culture, human adipose-derived mesenchymal stem cells | magnetic field, 50/60 Hz, low frequency | - |
Salinas-Asensio MM et al. | 2019 | - | magnetic field, 50/60 Hz, low frequency, signals/pulses, co-exposure, therapeutic/medical device | - |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.